General description
A cyanopyrrolidine compound that acts as a potent DPP IV inhibitor (IC50 = 3, 5, 8, and 8 nM in inhibiting rat, human, monkey, and canine DDP IV, respectively). Oral administration of K579 in rats in vivo has been shown to reduce blood DPP IV activity and augment GLP-1 and insulin response after glucose intake and significantly reduce plasma glucose concentration.
Please note: 328.4 is the anhydrous molecular weight; please refer to the vial label for the lot-specific hydration and molecular weight.
Packaging
Packaged under inert gas
Other Notes
Please note: 328.4 is the anhydrous molecular weight; please refer to the vial label for the lot-specific hydration and molecular weight.
Takasaki, K., et al. 2004. Eur. J. Pharmacol.505, 237.
Takasaki, K., et al. 2004. Eur. J. Pharmacol.486, 335.
Takasaki, K., et al. 2004. J. Pharmacol. Sci.95, 291.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
| Quality Level | 100 |
| assay | ≥97% (HPLC) |
| form | solid |
| manufacturer/tradename | Calbiochem® |
| storage condition | OK to freeze,protect from light |
| color | off-white to light brown |
| solubility | 1 M HCl: 16 mg/mL,DMSO: 32 mg/mL,ethanol: 6.5 mg/mL |
| shipped in | ambient |
| storage temp. | 2-8°C |
| SMILES string | N3([C@@H](CCC3)C#N)C(=O)CNC1(CCN(CC1)c2ncccn2)C |
| InChI | 1S/C17H24N6O/c1-17(21-13-15(24)23-9-2-4-14(23)12-18)5-10-22(11-6-17)16-19-7-3-8-20-16/h3,7-8,14,21H,2,4-6,9-11,13H2,1H3/t14-/m0/s1 |
| InChI key | JERPHRNGJBSFAP-AWEZNQCLSA-N |
